Skip to main content

Advertisement

SpringerLink
Log in

Bone-Muscle Mutual Interactions

  • Muscle and Bone (A Bonetto and M Brotto, Section Editors)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to describe the current state of our thinking regarding bone-muscle interactions beyond the mechanical perspective.

Recent Findings

Recent and prior evidence has begun to dissect many of the molecular mechanisms that bone and muscle use to communicate with each other and to modify each other’s function. Several signaling factors produced by muscle and bone have emerged as potential mediators of these biochemical/molecular interactions. These include muscle factors such as myostatin, Irisin, BAIBA, IL-6, and the IGF family and the bone factors FGF-23, Wnt1 and Wnt3a, PGE2, FGF9, RANKL, osteocalcin, and sclerostin.

Summary

The identification of these signaling molecules and their underlying mechanisms offers the very real and exciting possibility that new pharmaceutical approaches can be developed that will permit the simultaneous treatments of diseases that often occur in combination, such as osteoporosis and sarcopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gomarasca M, Banfi G, Lombardi G. Myokines: the endocrine coupling of skeletal muscle and bone. Adv Clin Chem. 2020;94:155–218.

    Article  PubMed  CAS  Google Scholar 

  2. • Trajanoska K, et al. Genetics of bone and muscle interactions in humans. Curr Osteoporos Rep. 2019;17(2):86–95 High Importance: This manuscript describes key pleiotropic loci that have been identified by multivariate GWAS studies.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bonewald L. Use it or lose it to age: a review of bone and muscle communication. Bone. 2019;120:212–8.

    Article  PubMed  Google Scholar 

  4. Karsenty G, Mera P. Molecular bases of the crosstalk between bone and muscle. Bone. 2018;115:43–9.

    Article  CAS  PubMed  Google Scholar 

  5. Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015;21:55–70.

    Article  CAS  PubMed  Google Scholar 

  6. Brotto M, Bonewald L. Bone and muscle: interactions beyond mechanical. Bone. 2015;80:109–14.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cianferotti L, Brandi ML. Muscle-bone interactions: basic and clinical aspects. Endocrine. 2014;45(2):165–77.

    Article  CAS  PubMed  Google Scholar 

  8. Brotto M, Johnson ML. Endocrine crosstalk between muscle and bone. Curr Osteoporos Rep. 2014;12(2):135–41.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Karasik D, Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone. 2010;46(5):1226–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Byrd HS, Spicer TE, Cierney G 3rd. Management of open tibial fractures. Plast Reconstr Surg. 1985;76(5):719–30.

    Article  CAS  PubMed  Google Scholar 

  11. Cierny G 3rd, Byrd HS, Jones RE. Primary versus delayed soft tissue coverage for severe open tibial fractures. A comparison of results. Clin Orthop Relat Res. 1983;178:54–63.

    Article  Google Scholar 

  12. Richards RR, Mahoney JL, Minas T. Influence of soft tissue coverage on the healing of cortical defects in canine diaphyseal bone. Ann Plast Surg. 1986;16(4):296–304.

    Article  CAS  PubMed  Google Scholar 

  13. Godina M. Early microsurgical reconstruction of complex trauma of the extremities. Plast Reconstr Surg. 1986;78(3):285–92.

    Article  CAS  PubMed  Google Scholar 

  14. Chan JK, et al. Soft-tissue reconstruction of open fractures of the lower limb: muscle versus fasciocutaneous flaps. Plast Reconstr Surg. 2012;130(2):284e–95e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cosman F, de Beur SJ, LeBoff M, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kull M, Kallikorm R, Lember M. Impact of a new sarco-osteopenia definition on health-related quality of life in a population-based cohort in Northern Europe. J Clin Densitom. 2012;15(1):32–8.

    Article  PubMed  Google Scholar 

  19. Binkley N, Buehring B. Beyond FRAX: it’s time to consider “sarco-osteopenia”. J Clin Densitom. 2009;12(4):413–6.

    Article  PubMed  Google Scholar 

  20. Sepulveda-Loyola W, et al. The joint occurrence of osteoporosis and sarcopenia (osteosarcopenia): definitions and characteristics. J Am Med Dir Assoc. 2020;21(2):220–5.

    Article  PubMed  Google Scholar 

  21. Kirk B, Al Saedi A, Duque G. Osteosarcopenia: a case of geroscience. Aging Med (Milton). 2019;2(3):147–56.

    Article  Google Scholar 

  22. Fatima M, Brennan-Olsen SL, Duque G. Therapeutic approaches to osteosarcopenia: insights for the clinician. Ther Adv Musculoskelet Dis. 2019;11:1759720x19867009.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Huo YR, Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Muir SW, et al. Phenotype of osteosarcopenia in older individuals with a history of falling. J Am Med Dir Assoc. 2015;16(4):290–5.

    Article  PubMed  Google Scholar 

  24. Ho-Pham LT, Nguyen UD, Nguyen TV. Association between lean mass, fat mass, and bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2014;99(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  25. Huh JH, Song MK, Park KH, Kim KJ, Kim JE, Rhee YM, et al. Gender-specific pleiotropic bone-muscle relationship in the elderly from a nationwide survey (KNHANES IV). Osteoporos Int. 2014;25(3):1053–61.

    Article  CAS  PubMed  Google Scholar 

  26. . Luo Y, Jiang K, He M. Association between grip strength and bone mineral density in general US population of NHANES 2013–2014. Arch Osteoporos. 2020;15(1):47 High Importance: This manuscript describes a US population study of hand grip strength and bone mineral density of the femoral neck and total lumbar spine. They found that grip strength can be associated with nonadjacent bones and grip strength of the dominant arm was highly correlated with BMD.

    Article  PubMed  Google Scholar 

  27. Locquet M, Beaudart C, Durieux N, Reginster JY, Bruyère O. Relationship between the changes over time of bone mass and muscle health in children and adults: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2019;20(1):429.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Karasik D, Kiel DP. Genetics of the musculoskeletal system: a pleiotropic approach. J Bone Miner Res. 2008;23(6):788–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Huang J, Hsu YH, Mo C, Abreu E, Kiel DP, Bonewald LF, et al. METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-kappaB signaling pathway. J Bone Miner Res. 2014;29(7):1531–40.

    Article  CAS  PubMed  Google Scholar 

  30. Medina-Gomez C, Kemp JP, Dimou NL, Kreiner E, Chesi A, Zemel BS, et al. Bivariate genome-wide association meta-analysis of pediatric musculoskeletal traits reveals pleiotropic effects at the SREBF1/TOM1L2 locus. Nat Commun. 2017;8(1):121.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281(10):6120–3.

    Article  CAS  PubMed  Google Scholar 

  32. Gorski JP, Huffman NT, Vallejo J, Brotto L, Chittur SV, Breggia A, et al. Deletion of Mbtps1 (Pcsk8, S1p, Ski-1) gene in osteocytes stimulates soleus muscle regeneration and increased size and contractile force with age. J Biol Chem. 2016;291(9):4308–22.

    Article  CAS  PubMed  Google Scholar 

  33. Gorski JP, Price JL. Bone muscle crosstalk targets muscle regeneration pathway regulated by core circadian transcriptional repressors DEC1 and DEC2. Bonekey Rep. 2016;5:850.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Samsa WE, Vasanji A, Midura RJ, Kondratov RV. Deficiency of circadian clock protein BMAL1 in mice results in a low bone mass phenotype. Bone. 2016;84:194–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Fu L, Patel MS, Bradley A, Wagner EF, Karsenty G. The molecular clock mediates leptin-regulated bone formation. Cell. 2005;122(5):803–15.

    Article  CAS  PubMed  Google Scholar 

  36. Andrews JL, Zhang X, McCarthy JJ, McDearmon EL, Hornberger TA, Russell B, et al. CLOCK and BMAL1 regulate MyoD and are necessary for maintenance of skeletal muscle phenotype and function. Proc Natl Acad Sci U S A. 2010;107(44):19090–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Riley LA, Esser KA. The role of the molecular clock in skeletal muscle and what it is teaching us about muscle-bone crosstalk. Curr Osteoporos Rep. 2017;15(3):222–30.

    Article  PubMed  PubMed Central  Google Scholar 

  38. . Qin W, Dallas SL. Exosomes and extracellular RNA in muscle and bone aging and crosstalk. Curr Osteoporos Rep. 2019; High Importance: This review discusses the role of extracellular vesicles in bone-muscle crosstalk.

  39. Ge M, Ke R, Cai T, Yang J, Mu X. Identification and proteomic analysis of osteoblast-derived exosomes. Biochem Biophys Res Commun. 2015;467(1):27–32.

    Article  CAS  PubMed  Google Scholar 

  40. Cui Y, Luan J, Li H, Zhou X, Han J. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression. FEBS Lett. 2016;590(1):185–92.

    Article  CAS  PubMed  Google Scholar 

  41. Deng L, Wang Y, Peng Y, Wu Y, Ding Y, Jiang Y, et al. Osteoblast-derived microvesicles: a novel mechanism for communication between osteoblasts and osteoclasts. Bone. 2015;79:37–42.

    Article  CAS  PubMed  Google Scholar 

  42. Huynh N, VonMoss L, Smith D, Rahman I, Felemban MF, Zuo J, et al. Characterization of regulatory extracellular vesicles from osteoclasts. J Dent Res. 2016;95(6):673–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Li D, Liu J, Guo B, Liang C, Dang L, Lu C, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat Commun. 2016;7(1):10872.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sun W, Zhao C, Li Y, Wang L, Nie G, Peng J, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity. Cell Discov. 2016;2:16015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Qin Y, Peng Y, Zhao W, Pan J, Ksiezak-Reding H, Cardozo C, et al. Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: a novel mechanism in muscle-bone communication. J Biol Chem. 2017;292(26):11021–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Veno PPM, Dusevich V, Bonewald L, Dallas S. Osteocytes release microvesicles that regulate osteoblast function. J Bone Miner Res. 2013;28(Suppl 1):S253.

    Google Scholar 

  47. Sato M, Suzuki T, Kawano M, Tamura M. Circulating osteocyte-derived exosomes contain miRNAs which are enriched in exosomes from MLO-Y4 cells. Biomed Rep. 2017;6(2):223–31.

    Article  CAS  PubMed  Google Scholar 

  48. Lai X, Price C, Lu X(L), Wang L. Imaging and quantifying solute transport across periosteum: implications for muscle-bone crosstalk. Bone. 2014;66:82–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pedersen BK, Febbraio M. Muscle-derived interleukin-6--a possible link between skeletal muscle, adipose tissue, liver, and brain. Brain Behav Immun. 2005;19(5):371–6.

    Article  CAS  PubMed  Google Scholar 

  50. Pedersen BK, et al. Role of myokines in exercise and metabolism. J Appl Physiol (1985). 2007;103(3):1093–8.

    Article  Google Scholar 

  51. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379–406.

    Article  CAS  PubMed  Google Scholar 

  52. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90.

    Article  CAS  PubMed  Google Scholar 

  53. Hamrick MW, McPherron AC, Lovejoy CO. Bone mineral content and density in the humerus of adult myostatin-deficient mice. Calcif Tissue Int. 2002;71(1):63–8.

    Article  CAS  PubMed  Google Scholar 

  54. Hamrick MW, Samaddar T, Pennington C, McCormick J. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res. 2006;21(3):477–83.

    Article  CAS  PubMed  Google Scholar 

  55. Grobet L, Royo Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet. 1997;17(1):71–4.

    Article  CAS  PubMed  Google Scholar 

  56. Kambadur R, Sharma M, Smith TPL, Bass JJ. Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res. 1997;7(9):910–6.

    Article  CAS  PubMed  Google Scholar 

  57. Smith TP, et al. Myostatin maps to the interval containing the bovine mh locus. Mamm Genome. 1997;8(10):742–4.

    Article  CAS  PubMed  Google Scholar 

  58. Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682–8.

    Article  CAS  PubMed  Google Scholar 

  59. Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40(6):1544–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Dankbar B, Fennen M, Brunert D, Hayer S, Frank S, Wehmeyer C, et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med. 2015;21(9):1085–90.

    Article  CAS  PubMed  Google Scholar 

  61. Chen Y-S, Guo Q, Guo LJ, Liu T, Wu XP, Lin ZY, et al. GDF8 inhibits bone formation and promotes bone resorption in mice. Clin Exp Pharmacol Physiol. 2017;44(4):500–8.

    Article  CAS  PubMed  Google Scholar 

  62. Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458–64.

    Article  CAS  PubMed  Google Scholar 

  63. Long KK, O’Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, et al. Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet. 2019;28(7):1076–89.

    Article  CAS  PubMed  Google Scholar 

  64. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Colaianni G, et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014;2014:–902186.

  66. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res. 2000;10(2):81–92.

    Article  CAS  PubMed  Google Scholar 

  67. Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17(9):1563–9.

    Article  CAS  PubMed  Google Scholar 

  68. Gimble JM, Nuttall ME. Bone and fat: old questions, new insights. Endocrine. 2004;23(2–3):183–8.

    Article  CAS  PubMed  Google Scholar 

  69. Confavreux CB, Levine RL, Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol. 2009;310(1–2):21–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A. 2015;112(39):12157–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Qiao X, Nie Y, Ma Y, Chen Y, Cheng R, Yin W, et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways. Sci Rep. 2016;6:18732.

    Article  CAS  PubMed  Google Scholar 

  72. Zhang J, Valverde P, Zhu X, Murray D, Wu Y, Yu L, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone research. 2017;5:–16056.

  73. Colaianni G, Mongelli T, Cuscito C, Pignataro P, Lippo L, Spiro G, et al. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci Rep. 2017;7(1):2811.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Kim H, et al. Irisin mediates effects on bone and fat via αV integrin receptors, 1756. Cell. 2018;175(7):–1768.e17.

  75. Storlino G, et al. Irisin prevents disuse-induced osteocyte apoptosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2019. https://doi.org/10.1002/jbmr.3944.

  76. Maisonneuve C, Igoudjil A, Begriche K, Lettéron P, Guimont MC, Bastin J, et al. Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting. Antivir Ther. 2004;9(5):801–10.

    Article  CAS  PubMed  Google Scholar 

  77. Note R, Maisonneuve C, Lettéron P, Peytavin G, Djouadi F, Igoudjil A, et al. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments. Antimicrob Agents Chemother. 2003;47(11):3384–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Igoudjil A, Abbey-Toby A, Begriche K, Grodet A, Chataigner K, Peytavin G, et al. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther. 2007;12(3):389–400.

    Article  CAS  PubMed  Google Scholar 

  79. Begriche K, et al. Beta-aminoisobutyric acid prevents diet-induced obesity in mice with partial leptin deficiency. Obesity (Silver Spring, Md). 2008, 2053-2067;(16):9.

  80. Begriche K, Massart J, Fromenty B. Effects of β-aminoisobutyric acid on leptin production and lipid homeostasis: mechanisms and possible relevance for the prevention of obesity. Fundam Clin Pharmacol. 2010;24(3):269–82.

    Article  CAS  PubMed  Google Scholar 

  81. Calvo JA, et al. Muscle-specific expression of PPARgamma coactivator-1alpha improves exercise performance and increases peak oxygen uptake. J Appl Physiol (1985). 2008;104(5):1304–12.

    Article  CAS  Google Scholar 

  82. Roberts LD, Boström P, O’Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al. beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014;19(1):96–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Kitase Y, Vallejo JA, Gutheil W, Vemula H, Jähn K, Yi J, et al. beta-Aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 2018;22(6):1531–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Zhu XW, Ding K, Dai XY, Ling WQ. β-aminoisobutyric acid accelerates the proliferation and differentiation of MC3T3-E1 cells via moderate activation of ROS signaling. J Chin Med Assoc. 2018;81(7):611–618. https://doi.org/10.1016/j.jcma.2017.12.005.

  85. Shi CX, Zhao MX, Shu XD, Xiong XQ, Wang JJ, Gao XY, et al. beta-Aminoisobutyric acid attenuates hepatic endoplasmic reticulum stress and glucose/lipid metabolic disturbance in mice with type 2 diabetes. Sci Rep. 2016;6:21924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Wang H, Qian J, Zhao X, Xing C, Sun B. beta-Aminoisobutyric acid ameliorates the renal fibrosis in mouse obstructed kidneys via inhibition of renal fibroblast activation and fibrosis. J Pharmacol Sci. 2017;133(4):203–13.

    Article  CAS  PubMed  Google Scholar 

  87. Wang Z, Bian L, Mo C, Shen H, Zhao LJ, Su KJ, et al. Quantification of aminobutyric acids and their clinical applications as biomarkers for osteoporosis. Commun Biol. 2020;3(1):39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK. Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol. 1998;508(Pt 3):949–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Nehlsen-Cannarella SL, et al. Carbohydrate and the cytokine response to 2.5 h of running. J Appl Physiol (1985). 1997;82(5):1662–7.

    Article  Google Scholar 

  90. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Pedersen BK. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529(Pt 1):237–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Hiscock N, Chan MHS, Bisucci T, Darby IA, Febbraio MA. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004;18(9):992–4.

    Article  CAS  PubMed  Google Scholar 

  92. Starkie RL, Angus DJ, Rolland J, Hargreaves M, Febbraio MA. Effect of prolonged, submaximal exercise and carbohydrate ingestion on monocyte intracellular cytokine production in humans. J Physiol. 2000;528(Pt 3):647–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Starkie RL, Rolland J, Angus DJ, Anderson MJ, Febbraio MA. Circulating monocytes are not the source of elevations in plasma IL-6 and TNF-alpha levels after prolonged running. Am J Phys Cell Phys. 2001;280(4):C769–74.

    CAS  Google Scholar 

  94. Juffer P, Jaspers RT, Klein-Nulend J, Bakker AD. Mechanically loaded myotubes affect osteoclast formation. Calcif Tissue Int. 2014;94(3):319–26.

    Article  CAS  PubMed  Google Scholar 

  95. Bakker AD, Kulkarni RN, Klein-Nulend J, Lems WF. IL-6 alters osteocyte signaling toward osteoblasts but not osteoclasts. J Dent Res. 2014;93(4):394–9.

    Article  CAS  PubMed  Google Scholar 

  96. McGregor NE, Murat M, Elango J, Poulton IJ, Walker EC, Crimeen-Irwin B, et al. IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis. J Biol Chem. 2019;294(19):7850–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Tresguerres FGF, Torres J, López-Quiles J, Hernández G, Vega JA, Tresguerres IF. The osteocyte: a multifunctional cell within the bone. Ann Anat. 2020;227:151422.

    Article  CAS  PubMed  Google Scholar 

  98. Han Y, You X, Xing W, Zhang Z, Zou W. Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018;6:16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord. 2015;16(2):93–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Schaffler MB, Cheung WY, Majeska R, Kennedy O. Osteocytes: master orchestrators of bone. Calcif Tissue Int. 2014;94(1):5–24.

    Article  CAS  PubMed  Google Scholar 

  101. Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell ... and more. Endocr Rev. 2013;34(5):658–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Pi M, Quarles LD. Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep. 2013;11(4):391–9.

    Article  PubMed  PubMed Central  Google Scholar 

  103. DiGirolamo DJ, Clemens TL, Kousteni S. The skeleton as an endocrine organ. Nat Rev Rheumatol. 2012;8(11):674–83.

    Article  CAS  PubMed  Google Scholar 

  104. Schaffler MB, Kennedy OD. Osteocyte signaling in bone. Curr Osteoporos Rep. 2012;10(2):118–25.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494–8.

    Article  CAS  PubMed  Google Scholar 

  106. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Ren Physiol. 2009;297(2):F282–91.

    Article  CAS  Google Scholar 

  108. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770–4.

    Article  CAS  PubMed  Google Scholar 

  110. Richter B, Faul C. FGF23 actions on target tissues-with and without Klotho. Front Endocrinol (Lausanne). 2018;9:189.

    Article  Google Scholar 

  111. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013;304(8):E863–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Kido S, Hashimoto Y, Segawa H, Tatsumi S, Miyamoto KI. Muscle atrophy in patients wirh ckd results from fgf23/klotho-mediated supression of insulin/igf-i signaling. Kidney Research and Clinical Practice. 2012;31(2):A44.

    Article  Google Scholar 

  114. Avin KG, Vallejo JA, Chen NX, Wang K, Touchberry CD, Brotto M, et al. Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility. Am J Physiol Endocrinol Metab. 2018;315(4):E594–e604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Wang K, le L, Chun BM, Tiede-Lewis LAM, Shiflett LA, Prideaux M, et al. A novel osteogenic cell line that differentiates into GFP-tagged osteocytes and forms mineral with a bone-like lacunocanalicular structure. J Bone Miner Res. 2019;34(6):979–95.

    Article  CAS  PubMed  Google Scholar 

  116. McCormick, L.A., et al., Role of FGF9 in promotion of early osteocyte differentiation and as a potent inducer of FGF23 expression in osteocytes. J Bone Mineral Res, 2016. American Society of Bone and Mineral Research (ASBMR Annual Meeting – Atlanta, GA 2016): p. Abstract 1122.

  117. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, et al. Endocrine regulation of male fertility by the skeleton. Cell. 2011;144(5):796–809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Chowdhury S, Schulz L, Palmisano B, Singh P, Berger JM, Yadav VK, et al. Muscle derived interleukin-6 increases exercise capacity by signaling in osteoblasts. J Clin Invest. 2020.

  119. Dole NS, Mazur CM, Acevedo C, Lopez JP, Monteiro DA, Fowler TW, et al. Osteocyte-intrinsic TGF-beta signaling regulates bone quality through perilacunar/canalicular remodeling. Cell Rep. 2017;21(9):2585–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Medeiros MC, et al. Serum sclerostin, body composition, and sarcopenia in hemodialysis patients with diabetes. Int J Nephrol. 2020;2020:4596920.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  122. Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, et al. Association of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcopenic Obesity Study (KSOS). Bone. 2019;128:115053.

    Article  CAS  PubMed  Google Scholar 

  123. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019;5.

  124. Girardi F, Le Grand F. Wnt signaling in skeletal muscle development and regeneration. Prog Mol Biol Transl Sci. 2018;153:157–79.

    Article  CAS  PubMed  Google Scholar 

  125. Rudnicki MA, Williams BO. Wnt signaling in bone and muscle. Bone. 2015;80:60–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Huang J, Romero-Suarez S, Lara N, Mo C, Kaja S, Brotto L, et al. Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/beta-catenin pathway. JBMR Plus. 2017;1(2):86–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Kamel MA, Picconi JL, Lara-Castillo N, Johnson ML. Activation of beta-catenin signaling in MLO-Y4 osteocytic cells versus 2T3 osteoblastic cells by fluid flow shear stress and PGE2: implications for the study of mechanosensation in bone. Bone. 2010;47(5):872–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol. 2012;6(3):223–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Mo C, Zhao R, Vallejo J, Igwe O, Bonewald L, Wetmore L, et al. Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation. Cell Cycle. 2015;14(10):1507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Bothwell W, Verburg M, Wynalda M, Daniels EG, Fitzpatrick FA. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. J Pharmacol Exp Ther. 1982;220(2):229–35.

    CAS  PubMed  Google Scholar 

  131. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–4.

    Article  CAS  PubMed  Google Scholar 

  133. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6(10):e25900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.

    Article  CAS  PubMed  Google Scholar 

  135. Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019;129(8):3214–23.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Hamoudi D, Bouredji Z, Marcadet L, Yagita H, Landry LB, Argaw A, et al. Muscle weakness and selective muscle atrophy in osteoprotegerin-deficient mice. Hum Mol Genet. 2020;29(3):483–94.

    Article  PubMed  CAS  Google Scholar 

  137. Boulanger Piette A, Hamoudi D, Marcadet L, Morin F, Argaw A, Ward L, et al. Targeting the muscle-bone unit: filling two needs with one deed in the treatment of Duchenne muscular dystrophy. Curr Osteoporos Rep. 2018;16(5):541–53.

    Article  PubMed  Google Scholar 

  138. Hamoudi D, Marcadet L, Piette Boulanger A, Yagita H, Bouredji Z, Argaw A, et al. An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum Mol Genet. 2019;28(18):3101–12.

    Article  CAS  PubMed  Google Scholar 

  139. Brun J, Berthou F, Trajkovski M, Maechler P, Foti M, Bonnet N. Bone regulates browning and energy metabolism through mature osteoblast/osteocyte PPARgamma expression. Diabetes. 2017;66(10):2541–54.

    Article  CAS  PubMed  Google Scholar 

  140. Mera P, Ferron M, Mosialou I. Regulation of energy metabolism by bone-derived hormones. Cold Spring Harb Perspect Med. 2018:8(6).

  141. Picca A, Calvani R, Manes-Gravina E, Spaziani L, Landi F, Bernabei R, et al. Bone-muscle crosstalk: unraveling new therapeutic targets for osteoporosis. Curr Pharm Des. 2017;23(41):6256–63.

    Article  CAS  PubMed  Google Scholar 

  142. Maurel DB, Jahn K, Lara-Castillo N. Muscle-bone crosstalk: emerging opportunities for novel therapeutic approaches to treat musculoskeletal pathologies. Biomedicines. 2017:5(4).

  143. Compston J. Emerging therapeutic concepts for muscle and bone preservation/building. Bone. 2015;80:150–6.

    Article  CAS  PubMed  Google Scholar 

  144. Girgis CM. Integrated therapies for osteoporosis and sarcopenia: from signaling pathways to clinical trials. Calcif Tissue Int. 2015;96(3):243–55.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

N.L-C. and MLJ are funded by a grant from the NIH NIA 2P01 AG039355 (Dr. Lynda F. Bonewald, Indiana University School of Medicine, PI)

Author information

Authors and Affiliations

  1. Department of Oral and Craniofacial Sciences, UMKC School of Dentistry, 650 East 25th Street, Kansas City, MO, 64108, USA

    Nuria Lara-Castillo & Mark L. Johnson

Authors
  1. Nuria Lara-Castillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark L. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark L. Johnson.

Ethics declarations

Conflict of Interest

Nuria Lara-Castillo and Mark L. Johnson declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Muscle and Bone

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lara-Castillo, N., Johnson, M.L. Bone-Muscle Mutual Interactions. Curr Osteoporos Rep 18, 408–421 (2020). https://doi.org/10.1007/s11914-020-00602-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-020-00602-6

Keywords

Search

Navigation